Rheumatoid Arthritis Clinical Trials in New York

Showing 221-240 of 3,596 trials

Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

NCT07447817

This is a phase II, multicenter, open-label trial evaluating the safety and efficacy of pacritinib and selinexor in JAK inhibitor naïve patients with anemia and thrombocytopenia.

MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis

John Mascarenhas26 participantsStarted May 2026

Westwood, Kansas, United States • New York, New York, United States • Winston-Salem, North Carolina, United States

RECRUITINGPhase 1< 1 mile

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

NCT06625775

First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.

Solid Tumor, AdultMetastatic Breast CancerAdvanced Breast Cancer+8 more

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)392 participantsStarted Oct 2024

Los Angeles, California, United States • San Diego, California, United States • San Francisco, California, United States +29 more locations

Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Rheumatoid Arthritis Trials in Other Cities

Topical Ketotifen 0.25% for Secondary Vestibulodynia

Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas

Evolut™ EXPAND TAVR II Pivotal Trial

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

Study of Long-Term Safety and Efficacy on Gene Therapy in Glycogen Storage Disease Type Ia

Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study

Epcoritamab in Previously Treated WM

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

Other Conditions in New York